"Serious Risks Uncovered: Weight-loss Drugs Linked to Stomach Paralysis and Pancreatitis"

A study from the University of British Columbia has found that weight-loss drugs known as GLP-1 agonists, including popular brands like Wegovy and Saxenda, are associated with increased risks of stomach paralysis, pancreatitis, and bowel obstruction. While these drugs were initially prescribed for managing Type 2 diabetes, they have gained popularity for weight management. The study revealed that users of GLP-1 agonists face significantly higher risks of these adverse events compared to those using bupropion-naltrexone, a drug for chronic obesity. Although these incidents are rare, the widespread use of these drugs could potentially lead to hundreds of thousands of people experiencing these conditions.